1
|
Flønes IH, Toker L, Sandnes DA, Castelli M, Mostafavi S, Lura N, Shadad O, Fernandez-Vizarra E, Painous C, Pérez-Soriano A, Compta Y, Molina-Porcel L, Alves G, Tysnes OB, Dölle C, Nido GS, Tzoulis C. Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease. Nat Commun 2024; 15:3631. [PMID: 38684731 PMCID: PMC11059185 DOI: 10.1038/s41467-024-47867-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 04/15/2024] [Indexed: 05/02/2024] Open
Abstract
Idiopathic Parkinson's disease (iPD) is believed to have a heterogeneous pathophysiology, but molecular disease subtypes have not been identified. Here, we show that iPD can be stratified according to the severity of neuronal respiratory complex I (CI) deficiency, and identify two emerging disease subtypes with distinct molecular and clinical profiles. The CI deficient (CI-PD) subtype accounts for approximately a fourth of all cases, and is characterized by anatomically widespread neuronal CI deficiency, a distinct cell type-specific gene expression profile, increased load of neuronal mtDNA deletions, and a predilection for non-tremor dominant motor phenotypes. In contrast, the non-CI deficient (nCI-PD) subtype exhibits no evidence of mitochondrial impairment outside the dopaminergic substantia nigra and has a predilection for a tremor dominant phenotype. These findings constitute a step towards resolving the biological heterogeneity of iPD with implications for both mechanistic understanding and treatment strategies.
Collapse
Affiliation(s)
- Irene H Flønes
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
- K.G. Jebsen Center for Translational Research in Parkinson's disease, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Lilah Toker
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
- K.G. Jebsen Center for Translational Research in Parkinson's disease, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Dagny Ann Sandnes
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Martina Castelli
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
| | - Sepideh Mostafavi
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Njål Lura
- Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway
- Section for Radiology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Omnia Shadad
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Erika Fernandez-Vizarra
- MRC-Mitochondrial Biology Unit, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK
- Veneto Institute of Molecular Medicine, 35131, Padova, Italy
| | - Cèlia Painous
- Parkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic I Universitari de Barcelona; IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (Maria de Maeztu excellence centre), Universitat de Barcelona, Barcelona, Catalonia, Spain
| | - Alexandra Pérez-Soriano
- Parkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic I Universitari de Barcelona; IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (Maria de Maeztu excellence centre), Universitat de Barcelona, Barcelona, Catalonia, Spain
- UParkinson - Sinapsi Neurología, Centre Mèdic Teknon Grup Hospitalari Quirón Salud, Barcelona, Spain
| | - Yaroslau Compta
- Parkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic I Universitari de Barcelona; IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (Maria de Maeztu excellence centre), Universitat de Barcelona, Barcelona, Catalonia, Spain
| | - Laura Molina-Porcel
- Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Neurological Tissue Bank, Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain
| | - Guido Alves
- The Norwegian Centre for Movement Disorders and Department of Neurology, Stavanger University Hospital, Pb 8100, 4068, Stavanger, Norway
- Department of Mathematics and Natural Sciences, University of Stavanger, 4062, Stavanger, Norway
| | - Ole-Bjørn Tysnes
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Christian Dölle
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
- K.G. Jebsen Center for Translational Research in Parkinson's disease, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Gonzalo S Nido
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway
- K.G. Jebsen Center for Translational Research in Parkinson's disease, University of Bergen, Pb 7804, 5020, Bergen, Norway
| | - Charalampos Tzoulis
- Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
- Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.
- K.G. Jebsen Center for Translational Research in Parkinson's disease, University of Bergen, Pb 7804, 5020, Bergen, Norway.
| |
Collapse
|
2
|
Pérez-Oliveira S, Castilla-Silgado J, Painous C, Aldecoa I, Menéndez-González M, Blázquez-Estrada M, Corte D, Tomás-Zapico C, Compta Y, Muñoz E, Lladó A, Balasa M, Aragonès G, García-González P, Rosende-Roca M, Boada M, Ruíz A, Pastor P, De la Casa-Fages B, Rabano A, Sánchez-Valle R, Molina-Porcel L, Álvarez V. Huntingtin CAG repeats in neuropathologically confirmed tauopathies: Novel insights. Brain Pathol 2024:e13250. [PMID: 38418081 DOI: 10.1111/bpa.13250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 02/09/2024] [Indexed: 03/01/2024] Open
Abstract
Previous studies have suggested a relationship between the number of CAG triplet repeats in the HTT gene and neurodegenerative diseases not related to Huntington's disease (HD). This study seeks to investigate whether the number of CAG repeats of HTT is associated with the risk of developing certain tauopathies and its influence as a modulator of the clinical and neuropathological phenotype. Additionally, it aims to evaluate the potential of polyglutamine staining as a neuropathological screening. We genotyped the HTT gene CAG repeat number and APOE-ℰ isoforms in a cohort of patients with neuropathological diagnoses of tauopathies (n=588), including 34 corticobasal degeneration (CBD), 98 progressive supranuclear palsy (PSP) and 456 Alzheimer's disease (AD). Furthermore, we genotyped a control group of 1070 patients, of whom 44 were neuropathologic controls. We identified significant differences in the number of patients with pathological HTT expansions in the CBD group (2.7%) and PSP group (3.2%) compared to control subjects (0.2%). A significant increase in the size of the HTT CAG repeats was found in the AD compared to the control group, influenced by the presence of the Apoliprotein E (APOE)-ℰ4 isoform. Post-mortem assessments uncovered tauopathy pathology with positive polyglutamine aggregates, with a slight predominance in the neostriatum for PSP and CBD cases and somewhat greater limbic involvement in the AD case. Our results indicated a link between HTT CAG repeat expansion with other non-HD pathology, suggesting they could share common neurodegenerative pathways. These findings support that genetic or histological screening for HTT repeat expansions should be considered in tauopathies.
Collapse
Affiliation(s)
- Sergio Pérez-Oliveira
- Laboratory of Genetics, Hospital Universitario Central de Asturias, Oviedo, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Juan Castilla-Silgado
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
- Department of Functional Biology (Physiology), University of Oviedo, Oviedo, Spain
| | - Cèlia Painous
- Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain
- UB Neuro Institut de Neurociències, Maeztu Center, University of Barcelona, Barcelona, Spain
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
| | - Iban Aldecoa
- Neurological Tissue Bank of the Biobank-Hospital Clinic-FRCB-IDIBAPS, Barcelona, Spain
- Pathology Department, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | - Manuel Menéndez-González
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
- Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain
- Department of Medicine, University of Oviedo, Oviedo, Spain
| | - Marta Blázquez-Estrada
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
- Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain
- Department of Medicine, University of Oviedo, Oviedo, Spain
| | - Daniela Corte
- Biobank of Principado de Asturias, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
| | - Cristina Tomás-Zapico
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
- Department of Functional Biology (Physiology), University of Oviedo, Oviedo, Spain
| | - Yaroslau Compta
- Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain
- UB Neuro Institut de Neurociències, Maeztu Center, University of Barcelona, Barcelona, Spain
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
| | - Esteban Muñoz
- Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain
- UB Neuro Institut de Neurociències, Maeztu Center, University of Barcelona, Barcelona, Spain
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
| | - Albert Lladó
- Biobank of Principado de Asturias, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
| | - Mircea Balasa
- Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, FRCB-IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Gemma Aragonès
- Neurological Tissue Bank of the Biobank-Hospital Clinic-FRCB-IDIBAPS, Barcelona, Spain
| | - Pablo García-González
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Maitée Rosende-Roca
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Mercè Boada
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Agustín Ruíz
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Pau Pastor
- Unit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol and The Germans Trias i Pujol Research Institute (IGTP) Badalona, Barcelona, Spain
| | - Beatriz De la Casa-Fages
- Movement Disorders Unit, Department of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic i Provincial de Barcelona and Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain
| | - Alberto Rabano
- Neuropathology Department and Brain Tissue Bank, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain
| | - Raquel Sánchez-Valle
- Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, FRCB-IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Laura Molina-Porcel
- UB Neuro Institut de Neurociències, Maeztu Center, University of Barcelona, Barcelona, Spain
- Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, FRCB-IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Victoria Álvarez
- Laboratory of Genetics, Hospital Universitario Central de Asturias, Oviedo, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| |
Collapse
|
3
|
Painous C, Pascual-Diaz S, Muñoz-Moreno E, Sánchez V, Pariente JC, Prats-Galino A, Soto M, Fernández M, Pérez-Soriano A, Camara A, Muñoz E, Valldeoriola F, Caballol N, Pont-Sunyer C, Martin N, Basora M, Tio M, Rios J, Martí MJ, Bargalló N, Compta Y. Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study. Eur Radiol 2023; 33:4540-4551. [PMID: 36773046 PMCID: PMC10290009 DOI: 10.1007/s00330-023-09435-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 10/19/2022] [Accepted: 01/08/2023] [Indexed: 02/12/2023]
Abstract
OBJECTIVES To conduct brainstem MRI shape analysis across neurodegenerative parkinsonisms and control subjects (CS), along with its association with clinical and cerebrospinal fluid (CSF) correlates. METHODOLOGY We collected demographic and clinical variables, performed planimetric and shape MRI analyses, and determined CSF neurofilament-light chain (NfL) levels in 84 participants: 11 CS, 12 with Parkinson's disease (PD), 26 with multiple system atrophy (MSA), 21 with progressive supranuclear palsy (PSP), and 14 with corticobasal degeneration (CBD). RESULTS MSA featured the most extensive and significant brainstem shape narrowing (that is, atrophy), mostly in the pons. CBD presented local atrophy in several small areas in the pons and midbrain compared to PD and CS. PSP presented local atrophy in small areas in the posterior and upper midbrain as well as the rostral pons compared to MSA. Our findings of planimetric MRI measurements and CSF NfL levels replicated those from previous literature. Brainstem shape atrophy correlated with worse motor state in all parkinsonisms and with higher NfL levels in MSA, PSP, and PD. CONCLUSION Atypical parkinsonisms present different brainstem shape patterns which correlate with clinical severity and neuronal degeneration. In MSA, shape analysis could be further explored as a potential diagnostic biomarker. By contrast, shape analysis appears to have a rather limited discriminant value in PSP. KEY POINTS • Atypical parkinsonisms present different brainstem shape patterns. • Shape patterns correlate with clinical severity and neuronal degeneration. • In MSA, shape analysis could be further explored as a potential diagnostic biomarker.
Collapse
Affiliation(s)
- C Painous
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - S Pascual-Diaz
- Magnetic Resonance Imaging Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Laboratory of Surgical Neuroanatomy (LSNA), Universitat de Barcelona, Barcelona, Spain
| | - E Muñoz-Moreno
- Magnetic Resonance Imaging Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - V Sánchez
- Centre de Diagnostic Per La Imatge (CDIC), Hospital Clinic, Barcelona, Spain
| | - J C Pariente
- Magnetic Resonance Imaging Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - A Prats-Galino
- Centre de Diagnostic Per La Imatge (CDIC), Hospital Clinic, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - M Soto
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - M Fernández
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - A Pérez-Soriano
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - A Camara
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - E Muñoz
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - F Valldeoriola
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - N Caballol
- UParkinson Centro Médico Teknon, Grupo Hospitalario Quirón Salud, Barcelona, Spain
- Department of Neurology, Hospital Sant Joan Despí Moisès Broggi and Hospital General de L'Hospitalet, Consorci Sanitari Integral, Barcelona, Spain
| | - C Pont-Sunyer
- Neurology Unit, Hospital General de Granollers, Universitat Internacional de Catalunya, Barcelona, Spain
| | - N Martin
- Department of Anaesthesiology, Hospital Clinic, Barcelona, Spain
| | - M Basora
- Department of Anaesthesiology, Hospital Clinic, Barcelona, Spain
| | - M Tio
- Department of Anaesthesiology, Hospital Clinic, Barcelona, Spain
| | - J Rios
- Medical Statistics Core Facility, IDIBAPS & Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain
| | - M J Martí
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain
| | - N Bargalló
- Magnetic Resonance Imaging Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
- Laboratory of Surgical Neuroanatomy (LSNA), Universitat de Barcelona, Barcelona, Spain.
- Neuroradiology Service, Hospital Clínic de Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
| | - Y Compta
- Parkinson's Disease & Movement Disorders Unit, Parkinson's Disease and Other Degenerative Movement Disorders Team, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (UBNeuro), Department of Medicine, School of Medicine, Universitat de Barcelona, Catalonia, Barcelona, Spain.
- Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Hospital Clínic de Barcelona, Institut de Neurociències (UBNeuro), Universitat de Barcelona, Catalonia, Barcelona, Spain.
- Neuroradiology Service, Hospital Clínic de Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
| |
Collapse
|
4
|
Torres V, Painous C, Santacruz P, Sánchez A, Sanz C, Grau‐Junyent JM, Muñoz E. Very Long Time Persistent
HyperCKemia
as the First Manifestation of
McLeod
Syndrome: A Case Report. Mov Disord Clin Pract 2022; 9:821-824. [DOI: 10.1002/mdc3.13502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 05/24/2022] [Accepted: 06/02/2022] [Indexed: 11/09/2022] Open
Affiliation(s)
- Viviana Torres
- Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociencies Hospital Clínic of Barcelona Barcelona Spain
| | - Cèlia Painous
- Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociencies Hospital Clínic of Barcelona Barcelona Spain
| | - Pilar Santacruz
- Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociencies Hospital Clínic of Barcelona Barcelona Spain
| | - Aurora Sánchez
- Biochemistry and Molecular Genetics Department Centre de Diagnòstic Biomèdic, Hospital Clínic of Barcelona Barcelona Spain
| | - Cristina Sanz
- Blood Bank and Transfusion Service Banc de Sang i Teixits, Hospital Clínic of Barcelona Barcelona Spain
| | - Josep M. Grau‐Junyent
- Laboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine Hospital Clínic of Barcelona Barcelona Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- University of Barcelona Barcelona Spain
| | - Esteban Muñoz
- Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociencies Hospital Clínic of Barcelona Barcelona Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- University of Barcelona Barcelona Spain
- European Reference Network‐Rare Neurological Diseases (ERN‐RND) Barcelona Spain
| |
Collapse
|
5
|
Illán-Gala I, Nigro S, VandeVrede L, Falgàs N, Heuer HW, Painous C, Compta Y, Martí MJ, Montal V, Pagonabarraga J, Kulisevsky J, Lleó A, Fortea J, Logroscino G, Quattrone A, Quattrone A, Perry DC, Gorno-Tempini ML, Rosen HJ, Grinberg LT, Spina S, La Joie R, Rabinovici GD, Miller BL, Rojas JC, Seeley WW, Boxer AL. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Netw Open 2022; 5:e229588. [PMID: 35486397 PMCID: PMC9055455 DOI: 10.1001/jamanetworkopen.2022.9588] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Accepted: 03/08/2022] [Indexed: 02/05/2023] Open
Abstract
Importance The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. Objective To assess and compare the diagnostic value of the magnetic resonance parkinsonism index (MRPI) and other magnetic resonance imaging-based measures of cerebral atrophy to differentiate between PSP, CBD, and other neurodegenerative diseases. Design, Setting, and Participants This prospective diagnostic study included participants with 4-repeat tauopathies (4RT), PSP, CBD, other neurodegenerative diseases and available MRI who appeared in the University of California, San Francisco, Memory and Aging Center database. Data were collected from October 27, 1994, to September 29, 2019. Data were analyzed from March 1 to September 14, 2021. Main Outcomes and Measures The main outcome of this study was the neuropathological diagnosis of PSP or CBD. The clinical diagnosis at the time of the MRI acquisition was noted. The imaging measures included the MRPI, cortical thickness, subcortical volumes, including the midbrain, pons, and superior cerebellar peduncle volumes. Multinomial logistic regression models (MLRM) combining different cortical and subcortical regions were defined to discriminate between PSP, CBD, and other pathologies. The areas under the receiver operating characteristic curves (AUROC) and cutoffs were calculated to differentiate between PSP, CBD, and other diseases. Results Of the 326 included participants, 176 (54%) were male, and the mean (SD) age at MRI was 64.1 (8.0) years. The MRPI showed good diagnostic accuracy for the differentiation between PSP and all other pathologies (accuracy, 87%; AUROC, 0.90; 95% CI, 0.86-0.95) and between 4RT and other pathologies (accuracy, 80%; AUROC, 0.82; 95% CI, 0.76-0.87), but did not allow the discrimination of participants with CBD. Its diagnostic accuracy was lower in the subgroup of patients without the canonical PSP-Richardson syndrome (PSP-RS) or probable corticobasal syndrome (CBS) at MRI. MLRM combining cortical and subcortical measurements showed the highest accuracy for the differentiation between PSP and other pathologies (accuracy, 95%; AUROC, 0.98; 95% CI, 0.97-0.99), CBD and other pathologies (accuracy, 83%; AUROC, 0.86; 95% CI, 0.81-0.91), 4RT and other pathologies (accuracy, 89%; AUROC, 0.94; 95% CI, 0.92-0.97), and PSP and CBD (accuracy, 91%; AUROC, 0.95; 95% CI, 0.91-0.99), even in participants without PSP-RS or CBS at MRI. Conclusions and Relevance In this study, the combination of widely available cortical and subcortical measures of atrophy on MRI discriminated between PSP, CBD, and other pathologies and could be used to support the diagnosis of 4RT in clinical practice.
Collapse
Affiliation(s)
- Ignacio Illán-Gala
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Atlantic Fellow for Equity in Brain Health at the University of California, San Francisco, Department of Neurology, University of California, San Francisco
- Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Salvatore Nigro
- Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari Aldo Moro, Pia Fondazione Cardinale G. Panico, Tricase, Lecce, Italy
- Institute of Nanotechnology, National Research Council, Lecce, Italy
| | - Lawren VandeVrede
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Neus Falgàs
- Atlantic Fellow for Equity in Brain Health at the University of California, San Francisco, Department of Neurology, University of California, San Francisco
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Hilary W. Heuer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Cèlia Painous
- Parkinson’s Disease & Movement Disorders Unit, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, CIBERNED, European Reference Network for Rare Neurological Diseases, Institut de Neurociències, Universitat de Barcelona, Catalonia, Spain
| | - Yaroslau Compta
- Parkinson’s Disease & Movement Disorders Unit, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, CIBERNED, European Reference Network for Rare Neurological Diseases, Institut de Neurociències, Universitat de Barcelona, Catalonia, Spain
| | - Maria J. Martí
- Parkinson’s Disease & Movement Disorders Unit, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, CIBERNED, European Reference Network for Rare Neurological Diseases, Institut de Neurociències, Universitat de Barcelona, Catalonia, Spain
| | - Victor Montal
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Javier Pagonabarraga
- Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
- Movement Disorders Unit, Sant Pau Hospital and Biomedical Research Institute, Barcelona, Spain
- Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jaime Kulisevsky
- Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
- Movement Disorders Unit, Sant Pau Hospital and Biomedical Research Institute, Barcelona, Spain
- Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Alberto Lleó
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Juan Fortea
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Giancarlo Logroscino
- Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari Aldo Moro, Pia Fondazione Cardinale G. Panico, Tricase, Lecce, Italy
- Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Andrea Quattrone
- Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy
| | - Aldo Quattrone
- Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy
- Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy
| | - David C. Perry
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | | | - Howard J. Rosen
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Lea T. Grinberg
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Salvatore Spina
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Renaud La Joie
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Gil D. Rabinovici
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Bruce L. Miller
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Julio C. Rojas
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - William W. Seeley
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| | - Adam L. Boxer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco
| |
Collapse
|
6
|
Planellas L, Mayà G, Painous C, Santacruz P, Santamaria J, Martí MJ. Characterization of sleep in six patients with pantothenate kinase-associated neurodegeneration. Sleep Med 2021; 84:389-396. [PMID: 34252845 DOI: 10.1016/j.sleep.2021.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Revised: 06/08/2021] [Accepted: 06/14/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND Pantothenate kinase-associated neurodegeneration (PKAN) is a rare neurologic disorder included in the group of neurodegeneration with brain iron accumulation diseases (NBIA). Information regarding sleep in patients with PKAN is limited. OBJECTIVES To describe the clinical and polysomnographic characteristics of sleep in six patients with genetically confirmed PKAN. METHODS The evaluation included a clinical interview, sleep questionnaires -Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI) and Hospital Anxiety and Depression Scale (HADS)- and a video-polysomnography (VPSG). In addition to standard sleep measures we manually quantified sleep spindle density in stage N2 and rapid eye movements in REM sleep comparing the results with matched controls. Quantification of EMG activity in REM sleep was performed following standard criteria. RESULTS All the patients reported at least one sleep complaint, most commonly sleep fragmentation (4/6) and sleep onset insomnia (3/6). ESS and PSQI were abnormal in 3/6 and 4/6, respectively. VPSG showed in 4/6 decreased ocular movements during REM sleep, an increase in sleep spindles in 3/6 (all of them with deep brain pallidal stimulation), an absence of slow wave sleep in 2 and undifferentiated NREM sleep and delayed sleep phase in one. Three patients had an abnormal sleep apnea/hypopnea index, and 2 periodic limb movements of sleep. REM sleep muscular atonia was preserved in all. CONCLUSIONS Sleep disorders are common in patients with PKAN. Although our sample is small and heterogeneous, with different symptomatic treatments possibly influencing the results, it suggests that evaluation of sleep should be considered in their management.
Collapse
Affiliation(s)
- Lluís Planellas
- Parkinson's Disease and Movement Disorders Unit, Neurology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
| | - Gerard Mayà
- Sleep Unit, Neurology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
| | - Cèlia Painous
- Parkinson's Disease and Movement Disorders Unit, Neurology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
| | - Pilar Santacruz
- Parkinson's Disease and Movement Disorders Unit, Neurology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
| | - Joan Santamaria
- Sleep Unit, Neurology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain.
| | - M J Martí
- Parkinson's Disease and Movement Disorders Unit, Neurology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain; European Reference Network for Rare Neurological Diseases - Project ID No 739510, Spain.
| |
Collapse
|
7
|
Cámara A, Compta Y, Pérez-Soriano A, Montagut N, Baixauli M, Maragall L, Ludeña E, Lopez de Los Reyes JC, Peri-Cusi L, Fernández N, Villote S, Ahuir M, Grau A, Caballol N, Buongiorno M, Pont-Sunyer C, Puente V, Giraldo DM, de Fabregues O, Garrido A, Navarro-Otano J, Painous C, Sánchez-Gómez A, Muñoz E, Zaro I, Obiang D, Valldeoriola F, Lombraña M, Martí MJ. Effects of COVID -19 pandemic and lockdown on people with multiple system atrophy participating in a therapeutic education program. Parkinsonism Relat Disord 2021; 86:78-80. [PMID: 33873000 PMCID: PMC8007182 DOI: 10.1016/j.parkreldis.2021.03.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 03/12/2021] [Accepted: 03/20/2021] [Indexed: 12/15/2022]
Affiliation(s)
- Ana Cámara
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain.
| | - Yaroslau Compta
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain.
| | - Alexandra Pérez-Soriano
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Núria Montagut
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Montserrat Baixauli
- Department of Urology, Clinical Instutue of Nephrology and Urology (ICNU)Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
| | - Laura Maragall
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Emma Ludeña
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | | | - Lluís Peri-Cusi
- Department of Urology, Clinical Instutue of Nephrology and Urology (ICNU)Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
| | - Noemí Fernández
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Susana Villote
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Maribel Ahuir
- Psychology Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
| | - Anna Grau
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Núria Caballol
- Movement Disorders Unit, Complex Hospitalari Moisès Broggi, Consorci Sanitari Integral, Sant Joan Despí, Catalonia, Spain and Movement Disorders Unit, UParkinson, Centro Médico Teknon, Grupo Hospitalario Quirón, Barcelona, Spain
| | - Mariateresa Buongiorno
- Movement Disorders Unit, Neurology. University Hospital Mutua de Terrassa, Terrassa, Catalonia, Spain
| | - Claustre Pont-Sunyer
- Movement Disorders Specialist, Hospital General de Granollers, Granollers, Catalonia, Spain
| | - Víctor Puente
- Movement Disorders Unit, Hospital Del Mar, Barcelona, Catalonia, Spain
| | - Darly M Giraldo
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain; Neurology Unit, Hospital Comarcal Sant Jaume de Calella, Calella, Catalonia, Spain
| | - Oriol de Fabregues
- Movement Disorders Unit, Hospital Vall d' Hebron, Barcelona, Catalonia, Spain
| | - Alícia Garrido
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Judith Navarro-Otano
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Cèlia Painous
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Almudena Sánchez-Gómez
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Esteban Muñoz
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Idoia Zaro
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Donina Obiang
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - Francesc Valldeoriola
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| | - María Lombraña
- Head of Nursery of the Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
| | - María-José Martí
- Parkinson's Disease & Movement Disorders Unit, Neurology Service, Clinical Institute of Neuroscience (ICN), Hospital Clínic de Barcelona / IDIBAPS / CIBERNED (CB06/05/0018-ISCIII) / European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències de la Universitat de Barcelona (Maria de Maeztu's Excellence Center), Catalonia, Spain
| |
Collapse
|
8
|
Cámara A, Compta Y, Pérez-Soriano A, Montagut N, Ahuir M, Ludeña E, Baixauli M, Peri-Cusi L, Fernández N, Villote S, Caballol N, Buongiorno M, Pont-Sunyer C, Puente V, Giraldo D, Garrido A, Painous C, Sánchez A, Muñoz E, Valldeoriola F, Lombraña M, Martí M. Healthcare education program in multiple system atrophy - preliminary results of satisfaction from a national registry based longitudinal study. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Iankova V, Respondek G, Saranza G, Painous C, Cámara A, Compta Y, Aiba I, Balint B, Giagkou N, Josephs KA, Otsuki M, Golbe LI, Bhatia KP, Stamelou M, Lang AE, Höglinger GU. Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism Relat Disord 2020; 78:200-203. [PMID: 32988736 DOI: 10.1016/j.parkreldis.2020.06.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Revised: 06/19/2020] [Accepted: 06/27/2020] [Indexed: 11/16/2022]
Abstract
BACKGROUND The International Parkinson and Movement Disorder Society-endorsed Progressive Supranuclear Palsy Study Group published clinical diagnostic criteria for progressive supranuclear palsy in 2017, aiming to optimize early, sensitive and specific diagnosis. OBJECTIVE To assist physicians in the application of these criteria, we developed a video-based tutorial in which all core clinical features and clinical clues are depicted and explained. METHODS Patients provided written informed consent to the publication of their videos. High-quality videos along with essential descriptions were collected by the study group members. Most educational videos were selected in a structured consensus process. RESULTS We provide 68 videos of all core clinical features and clinical clues defined by the diagnostic criteria, along with instructive descriptions of the depicted patients, examination techniques and clinical findings. CONCLUSIONS This comprehensive video-based tutorial will support physicians in the application of the diagnostic criteria of progressive supranuclear palsy.
Collapse
Affiliation(s)
- Vassilena Iankova
- Department of Neurology, Technische Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Gesine Respondek
- Department of Neurology, Technische Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Gerard Saranza
- The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada
| | - Cèlia Painous
- Parkinson's Disease & Movement Disorders Unit, Hospital Clínic, IDIBAPS, CIBERNED, European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències, Universitat de Barcelona (Maria de Maeztu Center), Catalonia, Spain
| | - Ana Cámara
- Parkinson's Disease & Movement Disorders Unit, Hospital Clínic, IDIBAPS, CIBERNED, European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències, Universitat de Barcelona (Maria de Maeztu Center), Catalonia, Spain
| | - Yaroslau Compta
- Parkinson's Disease & Movement Disorders Unit, Hospital Clínic, IDIBAPS, CIBERNED, European Reference Network for Rare Neurological Diseases (ERN-RND), Institut de Neurociències, Universitat de Barcelona (Maria de Maeztu Center), Catalonia, Spain
| | - Ikuko Aiba
- Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan
| | - Bettina Balint
- Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK; Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - Nikolaos Giagkou
- Parkinson's Disease and Movement Disorders Dept, HYGEIA Hospital, Athens, Greece
| | | | - Mika Otsuki
- Faculty of Health Sciences, Hokkaido University, Sapporo, Japan
| | - Lawrence I Golbe
- Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Kailash P Bhatia
- Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK
| | - Maria Stamelou
- Parkinson's Disease and Movement Disorders Dept, HYGEIA Hospital, Athens, Greece; First Department of Neurology, Aiginiteion Hospital, National and Kapodistrian University of Athens, Athens, Greece; Neurology Clinic, Philipps University, Marburg, Germany
| | - Anthony E Lang
- The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada
| | - Günter U Höglinger
- Department of Neurology, Technische Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Department of Neurology, Hannover Medical School, Hannover, Germany.
| | | |
Collapse
|
10
|
Painous C, van Os NJH, Delamarre A, Michailoviene I, Marti MJ, van de Warrenburg BP, Meissner WG, Utkus A, Reinhard C, Graessner H, Tijssen MA. Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases. Eur J Neurol 2020; 27:1493-1500. [PMID: 32386078 PMCID: PMC7496702 DOI: 10.1111/ene.14302] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 04/27/2020] [Indexed: 01/05/2023]
Abstract
Background and purpose The diagnosis of rare movement disorders is difficult and specific management programmes are not well defined. Thus, in order to capture and assess care needs, the European Reference Network for Rare Neurological Diseases has performed an explorative care need survey across all European Union (EU) countries. Methods This is a multicentre, cross‐sectional study. A survey about the management of different rare movement disorders (group 1, dystonia, paroxysmal dyskinesia and neurodegeneration with brain iron accumulation; group 2, ataxias and hereditary spastic paraparesis; group 3, atypical parkinsonism; group 4, choreas) was sent to an expert in each group of disorders from each EU country. Results Some EU countries claimed for an increase of teaching courses. Genetic testing was not readily available in a significant number of countries. Regarding management, patients’ accessibility to tertiary hospitals, to experts and to multidisciplinary teams was unequal between countries and groups of diseases. The availability of therapeutic options, such as botulinum toxin or more invasive treatments like deep brain stimulation, was limited in some countries. Conclusions The management of these conditions in EU countries is unequal. The survey provides evidence that a European care‐focused network that is able to address the unmet rare neurological disease care needs and inequalities is highly warranted.
Collapse
Affiliation(s)
- C Painous
- Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic Universitari, University of Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
| | - N J H van Os
- Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
| | - A Delamarre
- Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France.,UMR 5293, CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France
| | - I Michailoviene
- Faculty of Medicine, Institute of Biomedical Sciences, Vilnius, Vilnius University, Lithuania
| | - M J Marti
- Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic Universitari, University of Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
| | - B P van de Warrenburg
- Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
| | - W G Meissner
- Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France.,UMR 5293, CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.,Department of Medicine, University of Otago, Christchurch, New Zealand.,New Zealand Brain Research Institute, Christchurch, New Zealand
| | - A Utkus
- Faculty of Medicine, Institute of Biomedical Sciences, Vilnius, Vilnius University, Lithuania
| | - C Reinhard
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.,Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
| | - H Graessner
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.,Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
| | - M A Tijssen
- Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.,Expertise Center Movement Disorders Groningen, University Medical Center Groningen, Groningen, The Netherlands
| |
Collapse
|
11
|
Painous C, López‐Pérez MÁ, Illa I, Querol L. Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient. Ann Clin Transl Neurol 2018; 5:499-501. [PMID: 29687027 PMCID: PMC5899910 DOI: 10.1002/acn3.539] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Accepted: 01/10/2018] [Indexed: 11/18/2022] Open
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy with NF155 antibodies (anti-NF155+) constitutes a specific chronic inflammatory demyelinating polyradiculoneuropathy subset with a high incidence of limb's tremor and poor response to conventional therapies. We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy anti-NF155+ with a severe tremor involving limbs, head and voice that responded very well to rituximab. This response correlated with a sharp decrease in the anti-NF155 titers. This case is the first report associating head and voice tremor to chronic inflammatory demyelinating polyradiculoneuropathy, reinforces the hypothesis of the cerebellar origin of this tremor and provides indirect evidence that the antibodies may be the cause of the tremor in these patients.
Collapse
Affiliation(s)
- Cèlia Painous
- Neuromuscular Diseases UnitDepartment of NeurologyHospital de la Santa Creu i Sant PauUniversitat Autònoma de BarcelonaBarcelonaSpain
| | | | - Isabel Illa
- Neuromuscular Diseases UnitDepartment of NeurologyHospital de la Santa Creu i Sant PauUniversitat Autònoma de BarcelonaBarcelonaSpain
- Centro para la Investigación Biomédica en Red en Enfermedades RarasCIBERER (Centre for Biomedical Network Research on Rare Diseases)MadridSpain
| | - Luis Querol
- Neuromuscular Diseases UnitDepartment of NeurologyHospital de la Santa Creu i Sant PauUniversitat Autònoma de BarcelonaBarcelonaSpain
- Centro para la Investigación Biomédica en Red en Enfermedades RarasCIBERER (Centre for Biomedical Network Research on Rare Diseases)MadridSpain
| |
Collapse
|
12
|
Prats‐Sánchez L, Guisado‐Alonso D, Painous C, Fayos F, Pascual‐Goñi E, Delgado‐Mederos R, Martínez‐Domeño A, Camps‐Renom P, Martí‐Fàbregas J. Insular damage, new‐onset atrial fibrillation and outcome after acute intracerebral hemorrhage. Eur J Neurol 2017; 25:491-496. [DOI: 10.1111/ene.13522] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 11/20/2017] [Indexed: 12/25/2022]
Affiliation(s)
- L. Prats‐Sánchez
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - D. Guisado‐Alonso
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - C. Painous
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - F. Fayos
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - E. Pascual‐Goñi
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - R. Delgado‐Mederos
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - A. Martínez‐Domeño
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - P. Camps‐Renom
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| | - J. Martí‐Fàbregas
- Biomedical Research Institute Sant Pau (IIB‐Sant Pau) Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain
| |
Collapse
|